Research analysts at StockNews.com started coverage on shares of Otonomy (NASDAQ:OTIC – Get Rating) in a research report issued to clients and investors on Monday. The firm set a "hold" rating on the biopharmaceutical company's stock.
Otonomy Price Performance
Shares of Otonomy stock opened at $0.01 on Monday. Otonomy has a 1 year low of $0.01 and a 1 year high of $2.54. The company has a market capitalization of $582,479.50, a P/E ratio of -0.01 and a beta of 1.54. The business has a 50 day moving average price of $0.08 and a 200 day moving average price of $0.10.
Get Otonomy alerts:Institutional Trading of Otonomy
Several institutional investors have recently made changes to their positions in OTIC. Two Sigma Investments LP boosted its position in Otonomy by 129.2% in the 3rd quarter. Two Sigma Investments LP now owns 142,183 shares of the biopharmaceutical company's stock valued at $42,000 after buying an additional 80,153 shares during the last quarter. Requisite Capital Management LLC acquired a new stake in Otonomy during the third quarter worth about $44,000. State Street Corp grew its position in Otonomy by 5.1% in the 1st quarter. State Street Corp now owns 182,239 shares of the biopharmaceutical company's stock worth $437,000 after purchasing an additional 8,839 shares during the last quarter. Lynx1 Capital Management LP grew its position in Otonomy by 7,609.6% in the 3rd quarter. Lynx1 Capital Management LP now owns 2,312,880 shares of the biopharmaceutical company's stock worth $682,000 after purchasing an additional 2,282,880 shares during the last quarter. Finally, Point72 Asset Management L.P. bought a new position in Otonomy in the 3rd quarter worth about $1,621,000. 41.23% of the stock is owned by hedge funds and other institutional investors.
About Otonomy
(Get Rating)
Otonomy, Inc operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss.
Read More
- Get a free copy of the StockNews.com research report on Otonomy (OTIC)
- MarketBeat Week in Review – 4/24 – 4/28
- How to Invest in the Top Grocery Stocks for This Year
- Array Technologies Brings Solar Flare To 2023 Earnings Forecast
- Best Bank Stocks to Invest in Ahead of Rising Interest Rates
- How to Invest in Farmland: 7 Simple Ways
Receive News & Ratings for Otonomy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy and related companies with MarketBeat.com's FREE daily email newsletter.